Biocon opens book for Syngene IPO

Indian pharma company spins off contract research arm, hoping markets will regain a solid footing after Monday's sharp fall.

Biocon opens book for Syngene IPO
Markets in need of careful handling

Indian pharma company Biocon launched a Rs5.28 billion to Rs5.5 billion $82.2 million to $85.7 million initial public offering in its clinical research arm Syngene International on Monday.

The deal had seemed well-timed, taking advantage of a stock market rally, which began in mid-June. The company will now be hoping Monday's sharp fall does not presage a new downswing.

The Sensex suffered its biggest one-day drop in two months yesterday, closing down...

To continue reading, please login or register for free

Click for more on: india | credit suisse | jefferies | axis capital | equity | ipo | pharma

Print Edition

FinanceAsia Print Edition